Table 1 Baseline objective cardiometabolic measures in men seen in the Heart Healthy clinic
From: Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
All (n = 55) | |
|---|---|
Age at visit (Range) | 67 (44, 82) |
Total cholesterol (Median, IQR) | 212 (176, 243.8) |
Low-density lipoprotein (n = 31, median, IQR) | 123.5 (97, 168) |
High-density lipoprotein (Median, IQR) | 52 (43.5, 59.3) |
Triglycerides (n = 31, median, IQR) | 159 (111, 205.3) |
Hemoglobin A1C (n = 29, median, IQR) | 5.9 (5.6, 6.2) |
Body mass index | |
Normal | 4 (7.3%) |
Overweight | 18 (32.7%) |
Obese | 33 (60%) |
Blood pressure at visit (n = 49, median) | |
Systolic | 137 |
Diastolic | 77 |
ASCVD risk score | |
< 5% | 1 (1.8%) |
5—7.5% | 1 (1.8%) |
7.5–20% | 14 (25.5%) |
> 20% | 14 (25.5%) |
NA | 25 (45.4%) |
Subsequent follow up | |
Yes | 16 (29.1%) |
No | 39 (70.9%) |